Aim: The aim of this study was to evaluate the efficacy of gadoxetic acid and gadopentate dimeglumine in the evaluation of liver metastases of patients with gastrointestinal malignancy by magnetic resonance. Patients and Methods: A total of 50 patients were diagnosed gastrointestinal malignancies histopathologically were included in the study and their hepatic metastases were examined by magnetic resonance for two contrast agent. Results: There was no statistically significant difference for these contrast agent at arterial, portal and late phase series. (p>0.05) But we found a statistically significant difference between the series obtained at the 20th minutes after administration of gadoxetic acid and late phase for gadopentate dimeglumine for hepatic parenchymal and metastatic lesion intensity. (p<0.05) After the administration of gadoxetic acid, arterial, portal, late phase and the 20th minute series intensity of hepatic enhancement significantly reduced. At this time there was not a significant enhancement of the metastatic lesions. (p>0.05) When the hepatic parenchymal enhancement increased and the enhancement of metastatic lesions reduced, thus the enhancement difference between normally hepatic parenchyma and metastatic lesions might help the detection of the lesions. Conclusion: Gadoxetic acid, a hepatoceluler contrast agent, have important diagnostic contribution to the assessment of the patients with liver metastases of gastrointestinal malignancies by magnetic resonance imaging.